Clinical Trial Search

Primary: Number of Participants Demonstrating 10% Change: Arm Ergometer and Lokomat Metabolic Cart VO2 Peak — 17; 13; 17; 12 participants

Primary: Incidence of AIDS-defining and Non-AIDS-defining Malignancy — 13.0; 8.9; 9.3; 18.2 Events per 1000 person-years of followup — p=0.002

Primary: Time to Progression Free Survival (PFS) — 25.9; 29.7 months — p=0.0081

Primary: Time to Progression (TTP) — 3.5 months

Primary: AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to Time 24 Hours of TAK-536 (Azilsartan) — 6350.3; 6871.7 ng*hr/mL

Primary: Pain During IUD Insertion at Various Time Points (See Description for Time Points) — 35.4; 34.3; 55.5; 51.6 units on a 100 mm visual analogue scale

Primary: Number of Participants With Solicited Local and Systemic Adverse Events (AEs) for 6-35 Months Old Group — 3; 4; 12; 2 participants

Primary: Peak Oxygen Consumption (Peak VO2) — 1.1; -0.1 ml*kg^-1*min^-1 — p=0.009

Primary: All Cause Mortality and Readmission at 30 Days. — 16; 28 participants — p=<0.05

Primary: Asthma Control Test (ACT) Scores — 25.00; 20.5; 24.00; 15.75 units on a scale

Primary: AUC (0-24) of Plasma Metformin — 7771; 5559; 7757 ng*h/mL — p=0.0018

Primary: Post-Release Opioid Relapse — 6; 15 participants

Primary: Percent Change From Baseline in Tumor Volume at 6 Months — 17 percentage change of tumor volume

Primary: Complete Response. — 47; 15 percentage of evaluable subjects

Primary: Cervicovaginal Fetal Fibronectin Level — 39.4 nanogram per milliliter